Clinical trial
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C…
NCT00347217 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00347217 |
|---|---|
| Title | Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event |
| Official title | An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Hypercholesteremia |
| Enrollment | 3,840 |
| Start date | Feb 1, 2006 |
| Completion | Jan 1, 2009 |
| First posted | Jul 4, 2006 |
| Last update posted | Aug 30, 2011 |
| Countries | Netherlands |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: